Combination studies involving bortezomib that include 8 or more MCL patients
| Regimen . | No. of patients . | Response % ORR (CR/CRu) . | Duration (months) . | Reference . |
|---|---|---|---|---|
| VcR-CVAD | 30 | 90 (77) | 3 yr PFS 63% | 59 |
| BEAM-V | 23 | 95% | 5 yr PFS 57% | 81 |
| RiPAD + C | 39 | 79 (59) | PFS 26 | 82 |
| Ibritumomab-tiuxetan V | 12 | 50 (41.7) | Not reported | 83 |
| RVD | 16 | 81 (44) | PFS 12 | 84 |
| Gemcitabine V | 26 | 60 (11.5) | PFS 11.4 | 85 |
| CHOP R-V | 32 | 91 (72) | 2 yr PFS 44% | 54 |
| RV | 19 | 58 | Not reported | 86 |
| RV | 14 | 29 (29) | PFS 1.9 | 87 |
| R-HyperCVAD V | 20 | 100 (95) | Not reported | 53 |
| Cytarabine VD | 8 | 50 (25) | PFS 5 | 58 |
| Regimen . | No. of patients . | Response % ORR (CR/CRu) . | Duration (months) . | Reference . |
|---|---|---|---|---|
| VcR-CVAD | 30 | 90 (77) | 3 yr PFS 63% | 59 |
| BEAM-V | 23 | 95% | 5 yr PFS 57% | 81 |
| RiPAD + C | 39 | 79 (59) | PFS 26 | 82 |
| Ibritumomab-tiuxetan V | 12 | 50 (41.7) | Not reported | 83 |
| RVD | 16 | 81 (44) | PFS 12 | 84 |
| Gemcitabine V | 26 | 60 (11.5) | PFS 11.4 | 85 |
| CHOP R-V | 32 | 91 (72) | 2 yr PFS 44% | 54 |
| RV | 19 | 58 | Not reported | 86 |
| RV | 14 | 29 (29) | PFS 1.9 | 87 |
| R-HyperCVAD V | 20 | 100 (95) | Not reported | 53 |
| Cytarabine VD | 8 | 50 (25) | PFS 5 | 58 |
BEAM-V, BCNU, etoposide, cytarabine, melphalan, and bortezomib (Velcade); RiPAD + C, rituximab, bortezomib (Velcade), doxorubicin, dexamethasone, and chlorambucil; RV, rituximab and bortezomib (Velcade); RVD, RV and dexamethasone; VD, bortezomib (Velcade) and dexamethasone.